Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?

E-resources

Peer reviewed Open access

Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?

Kapadia, Sonam; Gudiwada, Sai Priyanka; Kaji, Amy H.; Chlebowski, Rowan T.; Venegas, Rose; Ozao‐Choy, Junko; Dauphine, Christine

The breast journal, November 2020, 2020-11-00, 20201101, Volume: 26, Issue: 11

Journal Article

Objective To determine if clinicopathologic (CP) factors could identify patients at “very low” and/or “very high” pretest probability of a high Oncotype DX (ODX) score. Methods A retrospective analysis of all patients that had ODX testing 2008‐2018 at a single institution. Results Of 215 patients, all 16 (7.4%) with “all high” risk CP factors had high ODX scores, and all 45 (20.9%) over age 50 with “all low” risk CP factors had ODX recommendations for no chemotherapy. Conclusions Oncotype DX results did not change chemotherapy recommendations in those with “very low” or “very high” pretest probability of high ODX scores.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme